HER-2 testing in breast cancer

Comment

Raymond R Tubbs et al. JAMA. 2004.

. 2004 Oct 20;292(15):1817-8; author reply 1818.

doi: 10.1001/jama.292.15.1817-b.

No abstract available

Comment on

HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. Yaziji H, et al. JAMA. 2004 Apr 28;291(16):1972-7. doi: 10.1001/jama.291.16.1972. JAMA. 2004. PMID: 15113815

High-quality HER-2 testing: setting a standard for oncologic biomarker assessment.
Wiley EL, Diaz LK. Wiley EL, et al. JAMA. 2004 Apr 28;291(16):2019-20. doi: 10.1001/jama.291.16.2019. JAMA. 2004. PMID: 15113823 No abstract available.
HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. Yaziji H, et al. JAMA. 2004 Apr 28;291(16):1972-7. doi: 10.1001/jama.291.16.1972. JAMA. 2004. PMID: 15113815
Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer.
Yaziji H, Gown AM. Yaziji H, et al. MLO Med Lab Obs. 2002 Jun;34(6):12-6, 20-1; quiz 22-3. MLO Med Lab Obs. 2002. PMID: 12090214
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A, Bronsard M, Lemieux R, Geha S. Akhdar A, et al. Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N. Chorn N. Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. doi: 10.1188/06.ONF.265-272. Oncol Nurs Forum. 2006. PMID: 16518442 Review.